Ngal is a precocious marker of therapeutic response

Current Pharmaceutical Design

Volumn 17, Issue 8, 2011, Pages 844-849

  Cernaro, Valeria ^a   Bolignano, Davide ^a   Donato, Valentina ^a   Lacquaniti, Antonio ^a   Buemi, Antoine ^a   Crascì, Eleonora ^a   Lucisano, Silvia ^a   Buemi, Michele ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Acute renal failure; Chronic kidney disease; Clinical nephrology; Clinical pharmacology; Ngal

Indexed keywords

BIOLOGICAL MARKER; CANDESARTAN; ERYTHROPOIETIN; IMMUNOGLOBULIN; INFLIXIMAB; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

BIOCHEMISTRY; CROHN DISEASE; DIABETIC NEPHROPATHY; DISEASE MARKER; DISEASE SEVERITY; DRUG MEGADOSE; GLOMERULONEPHRITIS; HUMAN; INFLAMMATION; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME; VASCULITIS;

ACUTE-PHASE PROTEINS; ANIMALS; BIOLOGICAL MARKERS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; LIPOCALINS; PROTO-ONCOGENE PROTEINS; TREATMENT OUTCOME;

EID: 79958290115     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795428939     Document Type: Review

References (34)

1. Flower DR. The lipocalin protein family: structure and function. Biochem J 1996; 15; 318 (Pt 1): 1-14.
2. Kjeldsen L, Cowland JB, Borregaard N. Human neutrophil gelatinase- associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta 2000; 18; 1482(1-2): 272-283.
3. Goetz DH, Willie ST, Armen RS, Bratt T, Borregaard N, Strong RK. Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry 2000; 29; 39(8): 1935-1941.
4. Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004; 432(7019): 917-921.
5. Borregaard N, Cowland JB. Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals 2006; 19(2): 211-215.
6. Miethke M, Skerra A. Neutrophil gelatinase-associated lipocalin expresses antimicrobial activity by interfering with Lnorepinephrine- mediated bacterial iron acquisition. Antimicrob Agents Chemother 2010; 54(4): 1580-1589.
7. Playford RJ, Belo A, Poulsom R, et al. Effects of mouse and human lipocalin homologues 24p3/lcn2 and neutrophil gelatinaseassociated lipocalin on gastrointestinal mucosal integrity and repair. Gastroenterology 2006; 131(3): 809-817.
8. Cowland JB, Sørensen OE, Sehested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J Immunol 2003; 171(12): 6630-6639.
9. Hemdahl AL, Gabrielsen A, Zhu C, et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006; 26(1): 136-142.
10. Bu DX, Hemdahl AL, Gabrielsen et al. Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. Am J Pathol 2006; 169(6): 2245-2253.
11. Bolignano D, Donato V, Coppolino G, et al. Neutrophil gelatinaseassociated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008; 52(3): 595-605.
12. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int 2007; 71: 967-970.
13. Hirsch R, Dent C, Pfriem H, et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 2007; 22: 2089-2095.
14. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinaseassociated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-1238.
15. Trachtman H, Christen E, Cnaan A, et al; Investigators of the HUSSYNSORB Pk Multicenter Clinical Trial. Urinary neutrophil gelatinase- associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr Nephrol 2006; 21: 989-994.
16. Mitsnefes MM, Kathman TS, Mishra J, et al. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol 2007; 22: 101-108.
17. Suzuki M, Wiers KM, Klein-Gitelman MS, et al. Neutrophil gelatinase- associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr Nephrol 2008; 23: 403-412.
18. Ding H, He Y, Li K, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol 2007; 123: 227-234.
19. Bolignano D, Coppolino G, Campo S, et al. Urinary neutrophil gelatinase- associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant 2008; 23: 414-416.
20. Bolignano D, Coppolino G, Campo S, et al. Neutrophil gelatinaseassociated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am J Nephrol 2007; 27: 373-378.
21. Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase- associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009; 4(2): 337-344.
22. Nykjaer A, Schambye H, Pedersen AH, Nielsen H. Assessing lowdose gentamicin-induced kidney injury in rats by analysis of urine. J Pharmacol Toxicol Methods 2009; 60(3): 316-320.
23. Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase- associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009; 32(2): 91-98.
24. Kunzendorf U, Haase M, Rölver L, Haase-Fielitz A. Novel aspects of pharmacological therapies for acute renal failure. Drugs 2010; 18; 70(9): 1099-1114.
25. Bolignano D, Coppolino G, Lacquaniti A, Buemi M. From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. Eur J Clin Invest 2010; 40(3): 273-276.
26. Bolignano D, Coppolino G, Aloisi C, Romeo A, Nicocia G, Buemi M. Effect of a single intravenous immunoglobulin infusion on neutrophil gelatinase-associated lipocalin levels in proteinuric patients with normal renal function. J Investig Med 2008; 56(8): 997-1003.
27. Bolignano D, Della Torre A, Lacquaniti A, Costantino G, Fries W, Buemi M. Neutrophil gelatinase-associated lipocalin levels in patients with crohn disease undergoing treatment with infliximab. J Investig Med 2010; 58(3): 569-571.
28. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M,Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996; 38(3): 414-420.
29. Nielsen OH, Gionchetti P, Ainsworth M, et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999; 94(10): 2923-2928.
30. MacDermott RP, Sanderson IR, Reinecker HC. The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 1998; 4(1): 54-67.
31. Kuwabara T, Mori K, Mukoyama M, et al. Urinary neutrophil gelatinase- associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int 2009; 75(3): 285-294.
32. Schick MA, Isbary TJ, Schlegel N, et al. The impact of crystalloid and colloid infusion on the kidney in rodent sepsis. Intensive Care Med 2010; 36(3): 541-548.
33. Moriyama MT, Tanaka T, Morita N, et al. Renal Protective Effects of Erythropoietin on Ischemic Reperfusion Injury. Cell Transplant 2010; 19(6): 713-721.
34. Kasahara M, Mori K, Satoh N, et al. Reduction in urinary excretion of neutrophil gelatinase-associated lipocalin by angiotensin receptor blockers in hypertensive patients. Nephrol Dial Transplant 2009; 24(8): 2608-2609.